



RECEIVED

Attorney Docket 054800-5008-01

TECH CENTER 1800 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Amy Arrow *et al.*

Application No. 09/211,794

Filed: December 15, 1998

For: Three Component Chimeric Antisense
Oligonucleotides

Examiner: Mary M. Schmidt

Group Art Unit: 1635

AMENDMENT UNDER 37 C.F.R. 1.114

In response to the Office Action dated July 30, 2001, the period for response having been extended to August 30, 2002 by the filing of a Notice of Appeal on January 30, 2002 and by the accompanying petition for a five-month extension of time, please amend this application as follows.

In the specification:

Please insert the following on page 1, line 3 of the specification:

--This is a continuation of U.S. Application 08/754,580 (filed November 21, 1996) now U.S. Patent 5,849,902.--

In the claims:

Please amend claims 1, 18 and 19 as follows:

1. (Once Amended) A chimeric antisense oligonucleotide comprising: a 5' terminus; a 3' terminus and from 11 to 59 5' → 3'-linked nucleotides which contiguously hybridize to a specific RNA and which are independently selected from the group consisting of 2'-modified phosphodiester nucleotides, and 2'-modified P-alkyloxyphosphotriester nucleotides; and wherein said 11 to 59 5' → 3'-linked nucleotides are divided by an RNase H-activating region which contiguously hybridizes to the specific RNA and comprises between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3' terminus of said oligonucleotide is drawn from the group consisting of: an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group, and a P-alkyloxyphosphodiester nucleotide, and wherein the 5' terminus of said oligonucleotide is drawn from the group consisting of: an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group, and a P-alkyloxyphosphodiester nucleotide.